Close Menu

Epigenomics

The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.

During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.